Completion of the Icatibant Outcome Survey and What We Learned

Laurence Bouillet; Werner Aberer; T. Caballero; Anete S. Grumach; Hilary J. Longhurst; Alissa Dangel; Natalie Khutoryansky; Irmgard Andresen; Andrea Zanichelli

doi:10.1111/cea.70271

March 10, 2026Clinical & Experimental AllergyOpen Access

Completion of the Icatibant Outcome Survey and What We Learned

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the long-term safety and effectiveness of icatibant in treating hereditary angioedema.
Creation of an observational registry for monitoring over 15 years
Data collection on icatibant use
Assessment of safety and effectiveness outcomes
Icatibant demonstrated effectiveness in managing hereditary angioedema symptoms
No new safety concerns were identified over the 15 years of use

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational registry monitors effectiveness and safety of icatibant in hereditary angioedema, indicating positive outcomes.

Abstract

Summary The Icatibant Outcome Survey observational registry began in 2009 to monitor the safety and effectiveness of icatibant. Fifteen years of icatibant use support effectiveness in hereditary angioedema, with no new safety signals.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bouillet et al. (2026) studied this question.

synapsesocial.com/papers/69b3ac2b02a1e69014ccd998 https://doi.org/10.1111/cea.70271

View Full Paper

Ask AI

Bookmark

Share

Completion of the Icatibant Outcome Survey and What We Learned

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Completion of the Icatibant Outcome Survey and What We Learned

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading